A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma
The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Abstract
HDAC8 inhibition elicits durable responses to immune checkpoint blockade by improving adaptive immune responses through enhancer reprogramming.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, most patients, especially patients with HCC, are unresponsive to the blockade of the PD-1/PD-L1 axis5,6.”
From PRDM1/BLIMP1 induces cancer immune evasion by modulating the USP22-SPI1-PD-L1 axis in hepatocellular carcinoma cells (2022) · cites this paper as [6]
Citations
Cites
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390
Metascape provides a biologist-oriented resource for the analysis of systems-level datasets
Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A. H., Tanaseichuk, O., Benner, C., & Chanda, S. K. (2019) · Nature Communications · doi:10.1038/s41467-019-09234-6 · Cited by 14,611
Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., & Salzberg, S. L. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r36 · Cited by 12,668
Trapnell, C., Roberts, A., Goff, L., Pertea, G., Kim, D., Kelley, D. R., Pimentel, H., Salzberg, S. L., Rinn, J. L., & Pachter, L. (2012) · Nature Protocols · doi:10.1038/nprot.2012.016 · Cited by 12,116
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791 · cited 21×
“In this immune-excluded phenotype, T cell migration through the tumor stroma is recognized as the rate-limiting step for ICB therapy, as CD8+ T cells show evidence of activation and proliferation, but not infiltration, upon treatment (1).”
BackgroundInfluentialElements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · cited 30×
“In this immune-excluded phenotype, T cell migration through the tumor stroma is recognized as the rate-limiting step for ICB therapy, as CD8+ T cells show evidence of activation and proliferation, but not infiltration, upon treatment (1).”
BackgroundInfluentialGREAT improves functional interpretation of cis-regulatory regions
McLean, C. Y., Bristor, D., Hiller, M., Clarke, S. L., Schaar, B. T., Lowe, C. B., Wenger, A. M., & Bejerano, G. (2010) · Nature Biotechnology · doi:10.1038/nbt.1630 · Cited by 4,502 · cited 2×
“C. Y. McLean, D. Bristor, M. Hiller, S. L. Clarke, B. T. Schaar, C. B. Lowe, A. M. Wenger, G. Bejerano, GREAT improves functional interpretation of cis-regulatory regions.”
BackgroundEl-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830 · cited 1×
“Our previous study has shown that HDAC8 cooperates with the enhancer of zeste homolog 2 repressor to epigenetically activate Wnt/-catenin signaling (51), which may result in subsequent defective recruitment of dendritic cells through reduced CCL4 and CCL5 expression (52), impaired T cell activity, and unresponsivenes…”
MethodAn atlas of active enhancers across human cell types and tissues
The FANTOM Consortium, Andersson, R., Gebhard, C., Miguel-Escalada, I., Hoof, I., Bornholdt, J., Boyd, M., Chen, Y., Zhao, X., Schmidl, C., et al. (2014) · Nature · doi:10.1038/nature12787 · Cited by 2,550 · cited 1×
“In conjunction with RNA sequencing (RNA-seq) data using the same tumor and nontumor tissue pairs, we found 1626 target genes of the aggregated Functional ANnoTation Of the Mammalian genome 5 (FANTOM5)–designated enhancer regions (33) that were recurrently down-regulated in more than half of the HCCs examined (Fig.”
BackgroundHistone modifications at human enhancers reflect global cell-type-specific gene expression
Heintzman, N. D., Hon, G. C., Hawkins, R. D., Kheradpour, P., Stark, A., Harp, L. F., Ye, Z., Lee, L. K., Stuart, R. K., Ching, C. W., et al. (2009) · Nature · doi:10.1038/nature07829 · Cited by 2,533
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Ally, A., Balasundaram, M., Carlsen, R., Chuah, E., Clarke, A., Dhalla, N., Holt, R. A., Jones, S. J. M., Lee, D., Ma, Y., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.046 · Cited by 2,490
Self-citationZhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30351-6 · Cited by 2,479
Self-citationChemokines in the cancer microenvironment and their relevance in cancer immunotherapy
Nagarsheth, N., Wicha, M. S., & Zou, W. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.49 · Cited by 2,206 · cited 1×
“2), we hypothesized that HDAC8 might modulate chemokine expression by epigenetic regulation of enhancers (38).”
BackgroundCD8 T Cell Exhaustion During Chronic Viral Infection and Cancer
McLane, L. M., Abdel-Hakeem, M. S., & Wherry, E. J. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-041015-055318 · Cited by 1,975 · cited 2×
“These findings are reminiscent of patients who do not respond to ICB therapy (53).”
BackgroundNew and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404 · cited 3×
“2 of 14 (HDACs), have become major targets for therapeutic development (11, 12).”
BackgroundFrom NASH to HCC: current concepts and future challenges
Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O., & Heikenwalder, M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0145-7 · Cited by 1,392
Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302 · cited 1×
“Because CTLA-4 blockade may function through enhancing CD8+ T cell infiltration, cytolytic activity, and T cell memory formation (9, 10), these studies further highlight the importance of cytotoxic T cell recruitment in overcoming the primary resistance of HCC tumors to ICB therapy.”
BackgroundSelf-citationHDACs and HDAC Inhibitors in Cancer Development and Therapy
Li, Y., & Seto, E. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026831 · Cited by 1,284
Yau, T., Kang, Y.-K., Kim, T.-Y., El-Khoueiry, A. B., Santoro, A., Sangro, B., Melero, I., Kudo, M., Hou, M.-M., Matilla, A., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.4564 · Cited by 1,273
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
Kamada, T., Togashi, Y., Tay, C., Ha, D., Sasaki, A., Nakamura, Y., Sato, E., Fukuoka, S., Tada, Y., Tanaka, A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1822001116 · Cited by 1,008 · cited 1×
“6D), which is possibly due to proliferation of PD-1+ Treg cells upon PD-L1 blockade (41).”
BackgroundIdentification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
Sia, D., Jiao, Y., Martinez-Quetglas, I., Kuchuk, O., Villacorta-Martin, C., Castro de Moura, M., Putra, J., Camprecios, G., Bassaganyas, L., Akers, N., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.06.007 · Cited by 976
Deacetylase inhibition promotes the generation and function of regulatory T cells
Tao, R., de Zoeten, E. F., Özkaynak, E., Chen, C., Wang, L., Porrett, P. M., Li, B., Turka, L. A., Olson, E. N., Greene, M. I., et al. (2007) · Nature Medicine · doi:10.1038/nm1652 · Cited by 924 · cited 1×
“Moreover, nonselective HDAC inhibition can enhance the production and immunosuppressive functions of regulatory T (Treg) cells and myeloid-derived suppressor cells (MDSCs) that may facilitate tumor growth (17, 18).”
BackgroundRuiz de Galarreta, M., Bresnahan, E., Molina-Sánchez, P., Lindblad, K. E., Maier, B., Sia, D., Puigvehi, M., Miguela, V., Casanova-Acebes, M., Dhainaut, M., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0074 · Cited by 912
Shen, L., Shao, N., Liu, X., & Nestler, E. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-284 · Cited by 887
A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia
Gröschel, S., Sanders, M. A., Hoogenboezem, R., de Wit, E., Bouwman, B. A. M., Erpelinck, C., van der Velden, V. H. J., Havermans, M., Avellino, R., van Lom, K., et al. (2014) · Cell · doi:10.1016/j.cell.2014.02.019 · Cited by 687 · cited 2×
“Genetic and epigenetic alterations of these noncoding sequences have emerged as common molecular traits across different types of human cancers (20, 21).”
BackgroundDe-novo and acquired resistance to immune checkpoint targeting
Syn, N. L., Teng, M. W. L., Mok, T. S. K., & Soo, R. A. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30607-1 · Cited by 662 · cited 21×
“In this immune-excluded phenotype, T cell migration through the tumor stroma is recognized as the rate-limiting step for ICB therapy, as CD8+ T cells show evidence of activation and proliferation, but not infiltration, upon treatment (1).”
BackgroundInfluentialButler, L. M., Agus, D. B., Scher, H. I., Higgins, B., Rose, A., Cordon‐Cardo, C., Thaler, H. T., Rifkind, R. A., Marks, P. A., & Richon, V. M. (2000) · PubMed · Cited by 615
Translational Implications of Tumor Heterogeneity
Jamal-Hanjani, M., Quezada, S. A., Larkin, J., & Swanton, C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1429 · Cited by 549 · cited 1×
“Given the intricate relationship between tumor heterogeneity and immunotherapy responses (58), an orthotopic mouse model using a cell line may not fully recapitulate immune surveillance during treatment.”
BackgroundMetabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy
Kishton, R. J., Sukumar, M., & Restifo, N. P. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.06.016 · Cited by 548 · cited 1×
“For examples, enhancer silencing of the lipid metabolism genes ACACB and PLAAT3 (34, 35) may heighten the metabolic activity of tumor cells to create a nutrient-depleted TME, thus reducing T cell metabolic fitness and antitumor functions (49, 50).”
BackgroundEpigenetic control of CD8+ T cell differentiation
Henning, A. N., Roychoudhuri, R., & Restifo, N. P. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.146 · Cited by 510 · cited 1×
“Given the importance of transcriptional and epigenetic regulation in T cell differentiation, exhaustion, and memory formation (53, 57), deciphering T cell–intrinsic HDAC8-controlled programs may enable rational design of combination strategies to protect patients with cancer from recurrence or relapse (43).”
Backgroundvan der Windt, D. J., Sud, V., Zhang, H., Varley, P. R., Goswami, J., Yazdani, H. O., Tohme, S., Loughran, P., O'Doherty, R. M., Minervini, M. I., et al. (2018) · Hepatology · doi:10.1002/hep.29914 · Cited by 477 · cited 1×
“To further investigate the therapeutic efficacy and durability of the combination immunotherapy, we used an additional spontaneous HCC model using HFHC diet-fed male C57BL/6 mice with neonatal STZ treatment, which closely resembles the characteristics of human NAFLD with consistent progression to HCC (64).”
MethodBalasubramanian, S., Ramos, J., Luo, W., Sirisawad, M., Verner, E., & Buggy, J. J. (2008) · Leukemia · doi:10.1038/leu.2008.9 · Cited by 458
Chromatin proteins and modifications as drug targets
Helin, K., & Dhanak, D. (2013) · Nature · doi:10.1038/nature12751 · Cited by 427 · cited 1×
“2 of 14 (HDACs), have become major targets for therapeutic development (11, 12).”
BackgroundPD-1 Blockade Expands Intratumoral Memory T Cells
Ribas, A., Shin, D. S., Zaretsky, J., Frederiksen, J., Cornish, A., Avramis, E., Seja, E., Kivork, C., Siebert, J., Kaplan-Lefko, P., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0210 · Cited by 405
Trujillo, J. A., Sweis, R. F., Bao, R., & Luke, J. J. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0277 · Cited by 393
Clinical Toxicities of Histone Deacetylase Inhibitors
Subramanian, S., Bates, S. E., Wright, J. J., Espinoza-Delgado, I., & Piekarz, R. L. (2010) · Pharmaceuticals · doi:10.3390/ph3092751 · Cited by 386
Zheng, H., Zhao, W., Yan, C., Watson, C. C., Massengill, M., Xie, M., Massengill, C., Noyes, D. R., Martinez, G. V., Afzal, R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2584 · Cited by 340
Self-citationEpigenomic Enhancer Profiling Defines a Signature of Colon Cancer
Akhtar-Zaidi, B., Cowper-Sal·lari, R., Corradin, O., Saiakhova, A., Bartels, C. F., Balasubramanian, D., Myeroff, L., Lutterbaugh, J., Jarrar, A., Kalady, M. F., et al. (2012) · Science · doi:10.1126/science.1217277 · Cited by 339
Corbet, C., Pinto, A., Martherus, R., Santiago de Jesus, J. P., Polet, F., & Feron, O. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.07.003 · Cited by 336 · cited 4×
“For example, we observed reduced expression and loss of H3K27ac signals at both promoter and H3K4me1-enriched distal enhancer regions of acetyl-CoA carboxylase beta (ACACB) and phospholipase A and acyltransferase 3 (PLAAT3; Fig.”
BackgroundInfluentialT cell metabolic fitness in antitumor immunity
Siska, P. J., & Rathmell, J. C. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.007 · Cited by 312 · cited 1×
“For examples, enhancer silencing of the lipid metabolism genes ACACB and PLAAT3 (34, 35) may heighten the metabolic activity of tumor cells to create a nutrient-depleted TME, thus reducing T cell metabolic fitness and antitumor functions (49, 50).”
BackgroundSharma, A., Subudhi, S. K., Blando, J., Vence, L., Wargo, J., Allison, J. P., Ribas, A., & Sharma, P. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0402 · Cited by 312 · cited 1×
“Because CTLA-4 blockade may function through enhancing CD8+ T cell infiltration, cytolytic activity, and T cell memory formation (9, 10), these studies further highlight the importance of cytotoxic T cell recruitment in overcoming the primary resistance of HCC tumors to ICB therapy.”
BackgroundEnhancer biology and enhanceropathies
Smith, E., & Shilatifard, A. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2784 · Cited by 311 · cited 2×
“These key regulatory elements are driven by the combinatorial assembly of lineage-determining transcription factors, coactivators, and bromodomain and extraterminal domain family proteins, which, in turn, recruit transcriptional complexes to acetylated lysine 27 of histone H3 (H3K27ac) (19).”
BackgroundEnamorado, M., Iborra, S., Priego, E., Cueto, F. J., Quintana, J. A., Martínez-Cano, S., Mejías-Pérez, E., Esteban, M., Melero, I., Hidalgo, A., et al. (2017) · Nature Communications · doi:10.1038/ncomms16073 · Cited by 293 · cited 1×
“Optimal antitumor immunity requires memory CD8+ T cells (54), which synergize with ICB for improved cancer immunotherapy (55).”
BackgroundHDAC8: a multifaceted target for therapeutic interventions
Chakrabarti, A., Oehme, I., Witt, O., Oliveira, G., Sippl, W., Romier, C., Pierce, R. J., & Jung, M. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.013 · Cited by 284 · cited 5×
“As other immune-excluded cancers such as colorectal and lung tumors also exhibit HDAC8 overexpression (23, 24), future studies are warranted to elucidate the effects of pharmacological HDAC8 inhibition in these tumors.”
BackgroundInfluentialTargeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat
Tate, C. R., Rhodes, L. V., Segar, H. C., Driver, J. L., Pounder, F. N., Burow, M. E., & Collins-Burow, B. M. (2012) · Breast Cancer Research · doi:10.1186/bcr3192 · Cited by 260
Jaworski, K., Ahmadian, M., Duncan, R. E., Sarkadi-Nagy, E., Varady, K. A., Hellerstein, M. K., Lee, H.-Y., Samuel, V. T., Shulman, G. I., Kim, K.-H., et al. (2009) · Nature Medicine · doi:10.1038/nm.1904 · Cited by 260
Chew, V., Lai, L., Pan, L., Lim, C. J., Li, J., Ong, R., Chua, C., Leong, J. Y., Lim, K. H., Toh, H. C., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1706559114 · Cited by 248
Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling
Mack, S. C., Pajtler, K. W., Chavez, L., Okonechnikov, K., Bertrand, K. C., Wang, X., Erkek, S., Federation, A., Song, A., Lee, C., et al. (2018) · Nature · doi:10.1038/nature25169 · Cited by 216
Zhou, J., Liu, M., Sun, H., Feng, Y., Xu, L., Chan, A. W. H., Tong, J. H., Wong, J., Chong, C. C. N., Lai, P. B. S., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-314032 · Cited by 201
Self-citationThe function and dysfunction of memory CD 8+ T cells in tumor immunity
Reading, J. L., Gálvez‐Cancino, F., Swanton, C., Lladser, A., Peggs, K. S., & Quezada, S. A. (2018) · Immunological Reviews · doi:10.1111/imr.12657 · Cited by 180 · cited 1×
“Optimal antitumor immunity requires memory CD8+ T cells (54), which synergize with ICB for improved cancer immunotherapy (55).”
BackgroundLiu, M., Zhou, J., Liu, X., Feng, Y., Yang, W., Wu, F., Cheung, O. K.-W., Sun, H., Zeng, X., Tang, W., et al. (2020) · Gut · doi:10.1136/gutjnl-2018-317257 · Cited by 176
Self-citationVHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma
Yao, X., Tan, J., Lim, K. J., Koh, J., Ooi, W. F., Li, Z., Huang, D., Xing, M., Chan, Y. S., Qu, J. Z., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0375 · Cited by 166
Self-citationAdeegbe, D. O., Liu, Y., Lizotte, P. H., Kamihara, Y., Aref, A. R., Almonte, C., Dries, R., Li, Y., Liu, S., Wang, X., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1020 · Cited by 149
Tian, Y., Wong, V. W. S., Wong, G. L. H., Yang, W., Sun, H., Shen, J., Tong, J. H. M., Go, M. Y. Y., Cheung, Y. S., Lai, P. B. S., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3786 · Cited by 133
Self-citationLiu, J. Y., Li, F., Wang, L. P., Chen, X. F., Wang, D., Cao, L., Ping, Y., Zhao, S., Li, B., Thorne, S. H., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.290 · Cited by 116
Zhao, W., Zhang, L., Xu, Y., Zhang, Z., Ren, G., Tang, K., Kuang, P., Zhao, B., Yin, Z., & Wang, X. (2014) · Laboratory Investigation · doi:10.1038/labinvest.2013.139 · Cited by 111 · cited 1×
“In an additional model, H22 hepatoma cells (5 × 105 cells in 10 l of PBS) originate from BALB/c mouse (60) were also intrahepatically injected into the left liver lobe of male BALB/c and NOD/SCID mice.”
MethodXiong, L., Wu, F., Wu, Q., Xu, L., Cheung, O. K.-W., Kang, W., Mok, M. T. S., Szeto, L. L. M., Lun, C.-Y., Lung, R. W. M., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08245-z · Cited by 111
Self-citationRosborough, B. R., Castellaneta, A., Natarajan, S., Thomson, A. W., & Turnquist, H. R. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0311119 · Cited by 77
HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF inhibitor therapy
Emmons, M. F., Faião-Flores, F., Sharma, R., Thapa, R., Messina, J. L., Becker, J. C., Schadendorf, D., Seto, E., Sondak, V. K., Koomen, J. M., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0040 · Cited by 73
Liu, M., Zhou, J., Chen, Z., & Cheng, A. S. L. (2016) · The Journal of Pathology · doi:10.1002/path.4832 · Cited by 72 · cited 10×
“Epigenetic therapy has gained further attention due to the widespread chromatin regulation in the milieu of immune and stromal cells within the TME (1, 13).”
BackgroundSelf-citationKelly‐Sell, M. J., Kim, Y. H., Straus, S., Benoit, B., Harrison, C., Sutherland, K., Armstrong, R., Weng, W., Showe, L. C., Wysocka, M., et al. (2012) · American Journal of Hematology · doi:10.1002/ajh.23112 · Cited by 68
Loss of tumor suppressor IGFBP4 drives epigenetic reprogramming in hepatic carcinogenesis
Lee, Y., Mok, M. T. S., Kang, W., Yang, W., Tang, W., Wu, F., Xu, L., Yan, M., Yu, Z., Lee, S.-D., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky589 · Cited by 65
Self-citationEpigenetic Activation of Wnt/β-Catenin Signaling in NAFLD-Associated Hepatocarcinogenesis
Tian, Y., Mok, M. T. S., Yang, P., & Cheng, A. S. L. (2016) · Cancers · doi:10.3390/cancers8080076 · Cited by 56 · cited 1×
“Our previous study has shown that HDAC8 cooperates with the enhancer of zeste homolog 2 repressor to epigenetically activate Wnt/-catenin signaling (51), which may result in subsequent defective recruitment of dendritic cells through reduced CCL4 and CCL5 expression (52), impaired T cell activity, and unresponsivenes…”
MethodSelf-citationStructure-activity relationships of HDAC8 inhibitors: Non-hydroxamates as anticancer agents
Amin, S. A., Adhikari, N., & Jha, T. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.03.001 · Cited by 53 · cited 4×
“RESULTS The antitumor activity of selective HDAC8 inhibition depends on adaptive immune responses Extensive studies have delineated the oncogenic signaling cascades induced by aberrant HDAC8 expression in cancer cells (23, 24), but its role in the tumor immune microenvironment is not known.”
BackgroundInfluentialTandem bispecific neutralizing antibody eliminates HIV-1 infection in humanized mice
Wu, X., Guo, J., Niu, M., An, M., Liu, L., Wang, H., Jin, X., Zhang, Q., Lam, K. S., Wu, T., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96764 · Cited by 50
Self-citationTan, Z., Zhou, J., Cheung, A. K. L., Yu, Z., Cheung, K., Liang, J., Wang, H., Lee, B. K., Man, K., Liu, L., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0473 · Cited by 36
Self-citationHa, S.-D., Reid, C., Meshkibaf, S., & Kim, S. O. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.695809 · Cited by 31
Booth, L. A., Roberts, J. L., Poklepovic, A. S., & Dent, P. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1507258 · Cited by 27 · cited 1×
“After the FDA approval of HDAC inhibitors such as vorinostat and romidepsin as anticancer agents (11), emerging studies have further demonstrated their immunomodulatory functions in promoting T cell infiltration into tumors, thus enhancing the efficacy of ICB in preclinical cancer models (14, 15).”
BackgroundImpacts of CCL4 gene polymorphisms on hepatocellular carcinoma susceptibility and development
Wang, B., Chou, Y., Lien, M., Su, C., Yang, S., & Tang, C. (2017) · International Journal of Medical Sciences · doi:10.7150/ijms.19620 · Cited by 17 · cited 1×
“Together with our complementary loss-of-function experiments, our data suggest that, mechanistically, aberrant expression of HDAC8 in tumor cells reduces H3K27 acetylation at certain enhancers required to reduce expression of T cell–trafficking chemokines such as CCL4 (39) whose gene polymorphisms have previously been…”
Background
Cited by
Evolving therapeutic landscape of advanced hepatocellular carcinoma
Yang, C., Zhang, H., Zhang, L., Zhu, A. X., Bernards, R., Qin, W., & Wang, C. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00704-9 · Cited by 727
The hallmarks of cancer immune evasion
Galassi, C., Chan, T. A., Vitale, I., & Galluzzi, L. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.09.010 · Cited by 565
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Zheng, J., Wang, S., Xia, L., Sun, Z., Chan, K. M., Bernards, R., Qin, W., Chen, J., Xia, Q., & Jin, H. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02075-w · Cited by 341
Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer
Wang, X., Fang, Y., Liang, W., Wong, C. C., Qin, H., Gao, Y., Liang, M., Song, L., Zhang, Y., Fan, M., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.08.019 · Cited by 247
Self-citationXu, L., Zou, C., Zhang, S., Chu, T. S. M., Zhang, Y., Chen, W., Zhao, C., Yang, L., Xu, Z., Dong, S., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01307-2 · Cited by 209
Self-citation
Metadata
- Authors
- Yang, W., Feng, Y., Zhou, J., Cheung, O. K.-W., Cao, J., Wang, J., Tang, W., Tu, Y., Xu, L., Wu, F., Tan, Z., Sun, H., Tian, Y., Wong, J., Lai, P. B.-S., Chan, S. L., Chan, A. W.-H., Tan, P. B.-O., Chen, Z., Sung, J. J.-Y., Yip, K. Y.-L., To, K.-F., & Cheng, A. S.-L.
- Affiliations
- Chinese University of Hong Kong (HK)
- School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong SAR 999077, China.
- University of Hong Kong (HK)
- Shanghai Jiao Tong University (CN)
- Shenzhen University (CN)
- SingHealth (SG)
- Sun Yat-sen University (CN)
- Corresponding author
- Yang, Weiqin
- Feng, Yu
- Zhou, Jingying
- Cheng, Alfred Sze-Lok
- ORCID
- Yang, Weiqin
- Feng, Yu
- Zhou, Jingying
- Cheung, Otto Ka-Wing
- Cao, Jianquan
- Wang, Jing
- Tang, Wenshu
- Tu, Yalin
- Xu, Liangliang
- Wu, Feng
- Tan, Zhiwu
- Tian, Yuan
- Wong, John
- Lai, Paul Bo-San
- Chan, Stephen Lam
- Chan, Anthony Wing-Hung
- Tan, Patrick Boon-Ooi
- Chen, Zhiwei
- Sung, Joseph Jao-Yiu
- Yip, Kevin Yuk-Lap
- To, Ka-Fai
- Cheng, Alfred Sze-Lok
- Venue
- Science Translational Medicine
- Published
- 2021-04-07
- Volume
- 13
- Issue
- 588
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W3198872327
- Cited by
- 172
- References
- 72
- Citations by year
- 2026: 30 · 2025: 45 · 2024: 40 · 2023: 23 · 2022: 27 · 2021: 7
- FWCI
- 9.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- DR-NTU (Nanyang Technological University) (submittedVersion)
- Funders
- Terry Fox Foundation
- Theme-based Research Scheme (T11-706/18-N)
- University Grants Committee through the Collaborative Research Fund (C4045-18W)
- The Focused Innovations Scheme-Scheme B from the Chinese University of Hong Kong (1907309)
- The Li Ka Shing Foundation
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Keywords
- hepatocellular carcinoma, immune checkpoint blockade, PD-L1 blockade, antitumor immunity, memory T cells, enhancer reprogramming, tumor rechallenge, combination therapy
- MeSH terms
- Immune Checkpoint Inhibitors, Animals, Carcinoma, Hepatocellular, Histone Deacetylases, Humans, Liver Neoplasms, Repressor Proteins, CD8-Positive T-Lymphocytes, Cell Line, Tumor, Mice, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.